Biotron Limited (ASX:BITO)

Australia · Delayed Price · Currency is AUD

0.0010

0.00 (0.00%)

At close: Jun 15, 2026

Market Cap	5.40M +103.6%
Revenue (ttm)	-868.00 +10.2%
Net Income	-1.94M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000,000
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0010 - 0.0010
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 10, 2026

About Biotron

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia. [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1999

Employees 3

Stock Exchange Australian Securities Exchange

Ticker Symbol BITO

Financial Performance

In fiscal year 2025, Biotron's revenue was 1.81 million, an increase of 10.24% compared to the previous year's 1.65 million. Losses were -318,572, -90.73% less than in 2024.

Financial Statements